Global Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They can ease symptoms of moderate to severe depression, are relatively safe and typically cause fewer side effects than other types of antidepressants do.
Due to the COVID-19 pandemic, the global Selective Serotonin Reuptake Inhibitors (SSRIs) market size was US$ 4788 million in 2022 and is forecast to a readjusted size of US$ 6118 million by 2034 with a CAGR of 3.5% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Citalopram (Celexa) accounting for % of the Selective Serotonin Reuptake Inhibitors (SSRIs) global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Depression segment is altered to an % CAGR throughout this forecast period.
With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market. Readers of the report can become informed about current and future trends of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market and how they will impact market growth during the forecast period.
Allergan Plc
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Pfizer Inc.
Segment by Type
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Paroxetine (Paxil, Pexeva)
Sertraline (Zoloft)
Vilazodone (Viibryd)
Depression
Anxiety and panic disorder
Other mental conditions
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Selective Serotonin Reuptake Inhibitors (SSRIs) in global and regional level.
Chapter 3Detailed analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Selective Serotonin Reuptake Inhibitors (SSRIs) revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Due to the COVID-19 pandemic, the global Selective Serotonin Reuptake Inhibitors (SSRIs) market size was US$ 4788 million in 2022 and is forecast to a readjusted size of US$ 6118 million by 2034 with a CAGR of 3.5% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Citalopram (Celexa) accounting for % of the Selective Serotonin Reuptake Inhibitors (SSRIs) global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Depression segment is altered to an % CAGR throughout this forecast period.
With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market. Readers of the report can become informed about current and future trends of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market and how they will impact market growth during the forecast period.
By Company
Allergan Plc
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Pfizer Inc.
Segment by Type
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Paroxetine (Paxil, Pexeva)
Sertraline (Zoloft)
Vilazodone (Viibryd)
Segment by Application
Depression
Anxiety and panic disorder
Other mental conditions
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Selective Serotonin Reuptake Inhibitors (SSRIs) in global and regional level.
Chapter 3Detailed analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Selective Serotonin Reuptake Inhibitors (SSRIs) revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices